×
About 330 results

ALLMedicine™ Acetylcholine Receptor Antibody Center

Research & Reviews  122 results

Thymectomy in ocular myasthenia gravis-prognosis and risk factors analysis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361517
Orphanet Journal of Rare Diseases; Zhang J, Zhang Z et. al.

Aug 10th, 2022 - Several retrospective studies have identified risk factors associated with ocular myasthenia gravis (OMG) generalization in non-surgical patients. However, the outcomes of OMG after thymectomy have not been investigated fully. This study aimed to ...

Serum pentraxin 3 concentration correlates with disease severity in patients with myast...
https://doi.org/10.1016/j.clineuro.2022.107371
Clinical Neurology and Neurosurgery; Kojima Y, Uzawa A et. al.

Jul 26th, 2022 - Myasthenia gravis (MG) is an antibody-mediated inflammatory disease affecting post-synaptic membranes of neuromuscular junctions, and objective biomarkers of MG disease activity are lacking. Pentraxin 3 (PTX3) is an acute-phase inflammatory glycop...

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT05403541

Jul 5th, 2022 - The purpose of this 3-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 3...

Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myast...
https://doi.org/10.1002/mus.27656
Muscle & Nerve; Suh J, Clarke V et. al.

Jun 11th, 2022 - Safety and outcomes data on eculizumab for generalized myasthenia gravis (gMG) in clinical practice remain limited. Outcomes and concomitant medication use may differ in practice compared with clinical trials. We analyzed the clinical and safety o...

Association Study Between VDR Gene Polymorphisms and Risk and Features of MG in Han Chinese Population
https://clinicaltrials.gov/ct2/show/NCT05380128

May 18th, 2022 - The Vitamin D receptor gene (VDR) polymorphisms are the candidate genetic variants for susceptibility to autoimmune diseases. In the present study, the investigators aimed to assess the association between VDR polymorphisms and myasthenia gravis (...

see more →

Clinicaltrials.gov  5 results

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT05403541

Jul 5th, 2022 - The purpose of this 3-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 3...

Association Study Between VDR Gene Polymorphisms and Risk and Features of MG in Han Chinese Population
https://clinicaltrials.gov/ct2/show/NCT05380128

May 18th, 2022 - The Vitamin D receptor gene (VDR) polymorphisms are the candidate genetic variants for susceptibility to autoimmune diseases. In the present study, the investigators aimed to assess the association between VDR polymorphisms and myasthenia gravis (...

Study on Correlation Between Cytomegalovirus and Ocular Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT05091177

Oct 25th, 2021 - A total of 75 patients and 40 healthy volunteers are collected who are diagnosed with ocular myasthenia gravis in the First Affiliated Hospital of Jinan University from January 2019 to January 2022 . All subjects undergo eye examination and cytome...

Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH
https://clinicaltrials.gov/ct2/show/NCT03350659

Apr 5th, 2019 - Visit 1. Enroll, baseline evaluation of the patients Questionnaire Evaluate orthostatic hypotension symptom: Orthostatic Hypotension Questionnaire (OHQ) Quality of life: Korean version of Short-form 36 Depressive symptom: Korean version of Beck De...

Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT01828294

Apr 3rd, 2019 - The study is a pilot study to ascertain the feasibility and tolerability of subcutaneous immunoglobulin (SCIG or IGSC) as a maintenance therapy for patients with non-thymomatous MG patients (MGFA class II-IV) at entry, aged 18-80 years, positive a...

see more →

News  5 results

First Human Bird Flu Case in U.S.; Okla. Nears Abortion Ban; Ebola Outbreak in DRC
https://www.medpagetoday.com/infectiousdisease/covid19/98463

Apr 29th, 2022 - Note that some links may require registration or subscription. CDC confirmed the first human case of the H5N1 bird flu in the U.S., in a Colorado man with direct exposure to birds. Oklahoma Gov. Kevin Stitt (R) is expected to sign a "Texas-style" ...

Potential First-in-Class, Targeted Therapy for Myasthenia Gravis
https://www.medscape.com/viewarticle/953330

Jun 17th, 2021 - Efgartigimod (argenx) is an effective and well-tolerated therapy for patients with generalized myasthenia gravis (gMG), new research suggests. Results from the phase 3, randomized, placebo-controlled ADAPT trial showed that reduction in disease bu...

Placebo response in negative rituximab BeatMG trial provides important lessons
https://www.mdedge.com/clinicalneurologynews/article/210310/neuromuscular-disorders/placebo-response-negative-rituximab/page/0/1?channel=39313

Oct 17th, 2019 - Suggestions from the data The post hoc subgroup analysis should be interpreted with caution, and the study does not provide firm conclusions, Dr. Nowak noted.

Cognitive Impairment and Autonomic Ganglionopathy
https://www.medscape.com/viewarticle/764741

Jun 5th, 2012 - Autoimmune Autonomic Ganglionopathy With Reversible Cognitive Impairment Gibbons CH, Centi J, Vernino S, Freeman R Arch Neurol. 2012;69:461-466 Study Summary Autoimmune autonomic ganglionopathy (AAG) is a rare form of severe autonomic failure link...

Myasthenia gravis therapy: Immunoadsorbent may eliminate need for plasma products
https://www.mdedge.com/ccjm/article/92699/myasthenia-gravis-therapy-immunoadsorbent-may-eliminate-need-plasma-products

Abstract This in vitro study assessed the effectiveness of a new immunoadsorbent (Asahi IM-TR 350) in removing anti-acetylcholine receptor antibody from plasma with minimal loss of albumin. Plasma procured from a myasthenia gravis patient undergoi.

see more →